More than 10,000 applications have been received for the IPO subscription of Skyalabs, with attention also focusing on the company's core medical device business and its growth potential after listing.

■ Subscription Status... Competition Ratio at 2.22 to 1 According to subscription figures on the 27th, Skyalabs' offer price was set at 10,000 won. The retail subscription volume is 500,000 shares, with Korea Investment & Securities as the lead underwriter. To date, the number of subscribers has been tallied at 11,690, with a proportional allocation competition ratio of around 2.22 to 1. Total subscription deposits amount to approximately 4 billion won. The minimum subscription unit is 10 shares, and the subscription fee is 2,000 won.

However, the competition ratio and the number of shares allocated in the equal allotment may change if additional funds flow in before the subscription closes. IPO subscriptions often see funds concentrated just before the deadline, so the final figures should be confirmed after the subscription period ends.

■ Core Product 'ART BP pro'... Replacing Conventional Cuff Method One of Skyalabs' main products is the 'ART BP pro'. Developed to replace conventional cuff-type ambulatory blood pressure monitors (ABPM), the device is a blood pressure monitor that tracks patients' 24-hour ambulatory blood pressure via hospital prescriptions.

ART BP pro received medical device approval from the Ministry of Food and Drug Safety in August 2023. In June 2024, it was subsequently approved by the Health Insurance Review and Assessment Service for the same reimbursement as the existing '24-hour ambulatory blood pressure measurement test (E6547)'.

■ Post-Listing Revenue Expansion Is Key Market analysis suggests that beyond this subscription competition ratio, it is also necessary to watch whether revenue from the medical device business centered on ART BP pro expands after listing. In particular, whether actual increased hospital adoption and growth in prescriptions translate into earnings is expected to be a key variable in future corporate valuation.

[Stock prices can exhibit heightened volatility depending on corporate performance, industry conditions, merger terms, and market supply and demand. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on specific stocks. Before making investment decisions, it is necessary to comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to recommend the purchase or sale of any specific stock. This article was written with AI assistance.]